Upcoming Conference Call for Third Quarter 2025 Results
ADC Therapeutics SA (NYSE: ADCT), a prominent leader in antibody drug conjugates, has scheduled a pivotal conference call and live webcast. This event will take place to communicate the financial results for the third quarter of 2025 and share a range of operational updates. The call is set for a morning slot at 8:30 a.m. EST on November 10, 2025.
How to Join the Conference Call
Participation in the conference call is straightforward. Interested individuals should ensure they register in advance. A dedicated toll-free dial-in number will be made available for North American and Canadian participants. It's suggested to join the call at least 10 minutes early to facilitate a smooth experience.
Accessing the Live Webcast
For those who prefer an online format, ADC Therapeutics will also host a live webcast. This will be accessible via the "Events and Presentations" section of the ADC Therapeutics investor website. Following the call, the webcast will remain archived for 30 days, allowing for further review and analysis.
About ADC Therapeutics: Innovators in Cancer Treatment
ADC Therapeutics stands at the forefront of innovation in the development of antibody drug conjugates (ADCs). Their approach aims to enhance treatment options available to patients battling cancer. One of the company's flagship products, ZYNLONTA (loncastuximab tesirine-lpyl), is notably recognized for receiving accelerated approval by the FDA. This groundbreaking treatment targets relapsed or refractory diffuse large B-cell lymphoma after multiple systemic therapies.
Focus on the Future: Development Projects
Beyond ZYNLONTA, ADC Therapeutics is actively pursuing the development of next-generation ADCs. Their commitment to research includes an intriguing PSMA-targeting ADC, which incorporates a unique exatecan-based payload paired with a novel hydrophilic linker. Such advancements showcase the company’s focus on evolving cancer therapies.
Global Presence and Commitment to Innovation
With headquarters in Lausanne, Switzerland, ADC Therapeutics maintains operations across London and New Jersey. This strategic positioning enables the company to leverage varied expertise and resources in both clinical development and manufacturing. They continuously endeavor to drive progress in the ADC space through their innovative strategies.
Leveraging Expertise for Patient Benefits
ADC Therapeutics aims to provide transformative solutions for patients. By enhancing its ADC product portfolio and pursuing innovative research avenues, the company strives to make a significant impact in cancer treatment. Their ongoing commitment to clinical trials and development activities is a testament to their dedication to patient care and industry advancement.
Frequently Asked Questions
What is the purpose of the conference call?
The conference call is aimed at reporting the financial results for the third quarter of 2025 and providing updates on operational activities.
How can I participate in the ADC Therapeutics call?
Participation can be done through dial-in numbers provided for North America and Canada, or via the live webcast available on their investor website.
What is ZYNLONTA?
ZYNLONTA is an antibody drug conjugate developed by ADC Therapeutics, aimed at treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Where is ADC Therapeutics located?
ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey.
What are ADC Therapeutics’ future plans?
ADC Therapeutics is focused on advancing their ADC technologies and exploring new treatment options for patients through ongoing research and development efforts.